Melanotan II has human signals, but no approved tanning product.
Tiny early studies recorded pigmentation and erection signals. They did not establish broad benefit, long-term safety, or a consumer use protocol. FDA and the Australian TGA now flag serious safety and product-quality concerns. This guide keeps every claim beside the exact evidence and its limit.
A real biological signal is not an approved or proven consumer product.
A three-person pilot reported increased pigmentation in two volunteers. Two ten-person crossover studies reported erectogenic signals. These small, short experiments do not establish routine effectiveness, long-term safety, weight loss, or a personal regimen.
FDA lists Melanotan II compounding concerns involving aggregation, peptide impurities, immunogenicity, and serious published case reports. The TGA says melanotan is not approved for sale or use as a tanning agent in Australia and warns that artificial pigmentation does not protect against ultraviolet damage.
Read the Melanotan II record in four fields.
This is a sourced status snapshot, not a safety score, treatment recommendation, or seller certification. Each field links back to the detailed record below.
Three tiny early studies
One pigmentation pilot enrolled 3 volunteers, and two ED crossover studies enrolled 10 men each.
Inspect the human evidenceSignals, not established use
Pigmentation and erection observations do not establish broad benefit, long-term safety, or a consumer regimen.
Audit the popular claimsNo FDA-approved product
FDA records describe marketed Melanotan II as an unapproved drug and flag current compounding safety concerns.
Check status and destination routesDated US price boards
Identity, human signals, safety reports, and legal status answer different questions.
Every Melanotan II claim should preserve the exact substance, product, route, source, population, study size, result, and destination country.
A cyclic heptapeptide, not a product guarantee
PubChem records Melanotan II as a cyclic seven-amino-acid peptide with formula C50H69N15O9 and CID 92432. Matching a name, sequence, or CAS number does not show that a seller product contains that identity, concentration, purity, sterility, or formulation.
Pigmentation and erection signals appeared in tiny studies
A three-person phase 1 pilot recorded increased pigmentation in two volunteers. Two crossover studies enrolled ten men each and recorded erectogenic signals. These experiments were short, small, and not designed to establish broad benefit, long-term safety, or a consumer tanning regimen.
Common effects and serious case reports are different evidence
Nausea, facial flushing, fatigue, appetite change, yawning, stretching, and spontaneous erections appear in early studies or regulator summaries. FDA also cites serious published case reports. Case reports can identify signals, but they cannot calculate incidence or prove causality by themselves.
Research activity does not create an approved product
FDA has treated marketed Melanotan II as an unapproved new drug and currently lists safety concerns for compounded preparations. Australia states that melanotan is not approved for sale or use as a tanning agent. Product and supply rules must still be checked country by country.
What the Melanotan II record shows, and what it cannot prove.
Each row puts the strongest relevant record beside the inference that still fails.
Melanotan II gives a safe sunless tan
A three-person pilot observed increased pigmentation in two volunteers after short Melanotan II exposure. The TGA also explains that melanotans can increase melanin production.
Three people cannot establish effectiveness across skin types or long-term safety. The TGA warns that artificial pigmentation does not protect skin from ultraviolet damage and that unapproved products may be poor quality, counterfeit, or mislabeled.
Melanotan II improves libido or erectile function
Two double-blind crossover studies enrolled ten men each and reported erectogenic signals after Melanotan II. Sexual-desire observations also appeared in the organic-risk-factor study.
These were tiny, short experiments from the early development record. They do not establish a current approved indication, durable effectiveness, comparative benefit, safe consumer use, or safety in a broader population.
Melanotan II causes weight loss by suppressing appetite
Decreased appetite appeared as an effect in early human studies, and appetite change is included in regulator safety summaries.
An observed adverse effect is not proof of safe or clinically meaningful weight loss. The cited record does not establish durable fat loss, muscle preservation, metabolic benefit, or an approved obesity treatment.
Third-party testing makes Melanotan II safe
A laboratory document can sometimes support a batch-specific identity, quantity, purity, or contamination result if the sample, method, date, and chain of custody are clear.
A report does not create FDA approval, establish clinical benefit, cover untested hazards, prove sterile handling after testing, or answer individual risk. FDA separately identifies aggregation, peptide-impurity, and immunogenicity concerns.
Melanotan II is the same as Vyleesi or Scenesse
Melanotan II, bremelanotide in Vyleesi, and afamelanotide in Scenesse are related to melanocortin biology and can collide in searches or seller language.
They are not the same finished product. FDA approval belongs to the exact Vyleesi and Scenesse products, applications, formulations, indications, manufacturing records, and labels. It does not transfer to Melanotan II.
Three small experiments and two serious case reports.
This is not a vote count. A controlled crossover study can detect a short-term signal. A case report can reveal a possible hazard. Neither alone establishes long-term effectiveness, incidence, or product-wide safety.
Pilot pigmentation and tolerability study
- Identity
- Melanotan II
- Design
- Single-blind, alternating saline and active exposure
- Participants
- 3 healthy male volunteers
Two volunteers had measured and visible pigmentation after exposure. Mild nausea was reported at most levels, and fatigue, somnolence, yawning, stretching, and spontaneous erections were observed. The sample is far too small for dependable effectiveness or safety estimates.
Psychogenic erectile dysfunction crossover study
- Identity
- Melanotan II
- Design
- Double-blind, placebo-controlled crossover
- Participants
- 10 men
Eight of ten participants developed clinically apparent erections after active exposure. Nausea, yawning, stretching, and decreased appetite occurred more often. A ten-person short experiment cannot establish an approved treatment or population safety profile.
Organic-risk-factor erectile dysfunction crossover study
- Identity
- Melanotan II
- Design
- Double-blind, placebo-controlled crossover
- Participants
- 10 men
The study reported erectogenic and desire signals. Nausea, stretching, and yawning were more frequent, and severe nausea occurred after four of nineteen active administrations. Scale, duration, and population sharply limit generalization.
Acute ischemic priapism case report
- Identity
- Seller-supplied product labelled Melanotan II
- Design
- Single published case
- Participants
- 1 patient
The report describes acute ischemic priapism after an injection. It is a serious signal that supports clinical awareness, but one case cannot establish frequency, comparative risk, dose response, or verified product composition.
Systemic toxicity and rhabdomyolysis case report
- Identity
- Internet-purchased product labelled Melanotan II
- Design
- Single published case
- Participants
- 1 patient
The report describes sympathomimetic symptoms, rhabdomyolysis, and renal dysfunction after exposure. The finding is clinically serious, while the single case and uncertain commercial supply chain prevent incidence or product-wide conclusions.
Melanotan II, Scenesse, and Vyleesi are not interchangeable.
Related biology, development history, or similar seller language does not transfer a finished medicine's approval to a different substance or product.
Separate research-market identity
A cyclic heptapeptide with early pigmentation and erection studies, no FDA-approved finished product in the cited record, and current regulator safety concerns.
Open the separate market board →Afamelanotide implant
FDA approval belongs to the exact SCENESSE implant and its narrowly defined EPP indication. It does not transfer to Melanotan I or Melanotan II seller products.
Open the FDA medicine record →Bremelanotide product
FDA approval belongs to Vyleesi under NDA 210557 for a defined HSDD population. PT-141 history or melanocortin biology does not make it Melanotan II.
Open the FDA medicine record →Research listings are easier to find than dependable product evidence.
These are dated US seller-page observations, not medical validation. Price and stock do not establish identity, purity, sterility, approval, seller authority, legal access, or individual suitability.
03
Three public US 10 mg pages met the current board rules. Every row preserves its source date, availability language, document route, and evidence limits.
Inspect every source row →01
Only explicit current stock language enters the available count. Ambiguous and out-of-stock rows stay visible for market context but do not set the available low.
Check source freshness →$36.99-36.99
The range excludes shipping, taxes, coupons, checkout-only discounts, and rows without a usable stock signal. It is market data, not a recommendation.
Compare landed cost →The next advisory meeting is planned, but its date is not set.
A safety-risk list, advisory discussion, committee recommendation, and final FDA action are separate records.
Potential significant safety risks
FDA cites aggregation, peptide-impurity, immunogenicity, and serious published case-report concerns for compounded Melanotan II.
Read the current FDA list →Advisory committee discussion planned
FDA says a meeting will occur before the end of February 2027. The time and location remain unannounced. Melanotan II is one of five listed bulk substances.
Track the official meeting page →Committee advice is non-binding
The committee advises FDA. A discussion or vote does not approve a finished product, establish a personal regimen, or decide every country's rules.
Open the safety center →Melanotan II rules depend on the exact destination and product.
Australia has a specific regulator warning and supply rule. US FDA records address unapproved drug marketing and compounding concerns. Italy, Canada, South Africa, the United Kingdom, and every other market require their own product, prescription, pharmacy, import, advertising, and seller checks.
Ten Melanotan II questions, answered from the current record.
This is educational reporting, not medical advice, a prescription, emergency guidance, or a use protocol.
What is Melanotan II?
Melanotan II, also searched as MT-II, MT2, or Melanotan 2, is a synthetic cyclic heptapeptide connected to melanocortin receptor research. PubChem records sequence XDHFRWK, molecular formula C50H69N15O9, molecular weight about 1024.2, CAS 121062-08-6, and CID 92432. A compound record establishes chemical identity vocabulary, not the contents or quality of an online product.
What benefits of Melanotan II are supported by human evidence?
The clearest human signals come from a three-person pigmentation pilot and two ten-person erectile-dysfunction crossover studies. Those studies observed pigmentation or erectogenic effects under short experimental conditions. They do not establish broad consumer tanning benefit, durable libido improvement, weight loss, long-term safety, comparative effectiveness, or a current approved medical use.
Does Melanotan II make you tan without sunlight?
A 1996 pilot reported increased pigmentation in two of three volunteers, so there is a small human pigmentation signal. That does not establish a safe tanning product or personal protocol. The Australian TGA warns that melanotan is not approved there as a tanning agent, that unapproved products may have uncertain contents, and that artificial pigmentation does not protect skin against ultraviolet damage.
What are the side effects of Melanotan II?
Early studies and regulator summaries include nausea, headache, vomiting, facial redness, appetite loss, fatigue, somnolence, yawning, stretching, and spontaneous erections. FDA also cites published serious reports involving melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome, and priapism. Case reports flag possible hazards but cannot establish how often an event occurs or prove causality alone.
Does Melanotan II cause melanoma or skin cancer?
The current record does not support a simple yes-or-no causal claim. FDA cites published melanoma case reports as a serious safety signal, while a case report cannot prove that Melanotan II caused a cancer or calculate incidence. The TGA warns about reports of changing moles and serious skin-cancer concerns. New or changing skin lesions require prompt professional evaluation, and a tan does not replace ultraviolet protection.
Is Melanotan II FDA approved?
No FDA-approved Melanotan II product is identified in the cited current record. FDA enforcement history describes marketed Melanotan II as an unapproved new drug. FDA also lists Melanotan II among nominated bulk substances with potential significant safety risks. A planned advisory committee discussion before the end of February 2027 is not approval and will provide non-binding advice.
Is Melanotan II legal in my country?
The answer depends on the exact product, intended claim, prescription status, supplier, import route, and destination. Australia says melanotan is not approved for sale or use as a tanning agent and restricts supply. US FDA records treat marketed Melanotan II as an unapproved drug. Other countries require their own medicine register, pharmacy, import, advertising, and seller checks. A shipping offer does not prove lawful access.
Are Melanotan I and Melanotan II the same?
No. The names are easy to confuse, but Melanotan I and Melanotan II are separate molecular and evidence records. Afamelanotide, the active ingredient in the FDA-approved Scenesse implant, is also associated with Melanotan I history. A seller-labelled Melanotan I vial is not Scenesse, and neither Melanotan I nor Scenesse should be treated as Melanotan II.
Is Melanotan II the same as PT-141 or Vyleesi?
No. PT-141 is a name associated with bremelanotide, the active ingredient in the FDA-approved Vyleesi product. Melanotan II and bremelanotide are related through melanocortin research history, but the finished substances and product records must remain separate. Vyleesi approval under NDA 210557 does not authorize or validate a Melanotan II vial, spray, seller, or use claim.
What is a safe Melanotan II dose?
There is no FDA-approved Melanotan II product label that supplies a self-use regimen for the products discussed here. Doses from tiny historical experiments, case reports, seller pages, forums, or unapproved products should not be converted into personal instructions. This guide does not provide dosing, reconstitution, injection, nasal-spray, cycling, stacking, or titration guidance.
Do not turn a tiny historical experiment into a personal protocol.
The studies describe controlled research conditions with very small samples. Online vials, sprays, tablets, creams, and seller instructions can differ in identity, formulation, concentration, impurities, sterility, storage, and exposure.
FDA approval, compounding eligibility, country access, product testing, seller availability, and individual medical care are separate records. This page does not provide dosing, reconstitution, injection, nasal-spray, cycling, stacking, or titration instructions.